http://www2.bioqmed.ufrj.br/ldn/matthias.htmlIn May 2015, the Department of Physiology and Medical Physics and CSM was pleased to host a guest scientist from the Instituto de Bioquímica Médica from the Universidade Federal do Rio de Janeiro in Brazil. Supported by RCSI through SFI/ISCA funding Prof. Gralle worked with Dr. Koenig in conjunction with Dr. Duessman and Prof. Prehn on the implementation of models for localised application of toxins relevant in Alzheimer’s disease and analysed their impact on sub cellular structures (05/05/2015-17/05/2015).
Congratulations to Dr Alice O’Farrell (Physiology & Medical Physics & Centre for Systems Medicine) who was awarded the 2015 Royal Academy of Medicine in Ireland (RAMI) Barcroft Medal at the Annual Meeting of the Biomedical Sciences Section, which was held at RCSI on June 18th. The Award was made for Alice’s presentation entitled “Cardiac Metabolic Pathway Remodelling in Response to Sunitinib Malate: Potential Role for Positron Emission Tomography in the Cardio-Oncology Setting”.
Congratulations to Dr. Amanda Tivinan who has been made Patron of the West Wicklow Cancer Support Group, in addition to setting up the IBTRI (Irish Brain Tumour Research Initiative) a platform for BT researchers throughout Ireland to liaise and collaborate, with future fund raising potential to benefit research here in RCSI.
Her recent publication was published in the Frontiers in Neuroscience journal http://journal.frontiersin.org/article/10.3389/fnins.2015.00218/abstract
Lecture entitled “NOS1AP, an adaptor protein linked to neurological diseases, reveals a novel signalling paradigm”
Venue: Albert L.T. 4pm 11th June 2015
Michael Courtney leads a research group focused on neuronal signaling mechanisms and is currently based at the Turku Centre for Biotechnology, Turku, Finland.
Research: After early investigations of the roles of
JNK signalling in neuronal death and development his group focused on
identifying targetable mechanisms by which NMDA receptor signaling influences
neuronal cell fate via activation of the p38MAPK pathway. One of the major NMDA
receptor pathways regulating p38MAPK involves the ternary complex of NMDA
receptor, PSD95 and nNOS. The lab demonstrated that PSD95/nNOS-dependent
pathways could be inhibited by nNOS-derived peptides, resulting in
neuroprotection. They showed that NMDA receptor activity leads to recruitment
of NOS1AP to nNOS and demonstrated that NOS1AP is required for NMDA-evoked
stress-activated MAPK responses and downstream excitotoxic consequences. They
developed a selective inhibitor peptide of the interaction between NOS1AP and
nNOS, with neuroprotective properties in cell cultures and in vivo (in a
preclinical model of perinatal asphyxia). More recently they identified that
interaction of nNOS with NOS1AP involves an unexpectedly complex interplay
between two distinct interaction sites. Each site is potentially druggable,
thereby providing increased opportunities for therapeutic intervention. This is
of potential interest considering that the NR-PSD95-nNOS complex and
potentially the recruitment of NOS1AP may be involved in some of the most
common causes of death and disability from stroke to neuropathic pain,
depression and anxiety disorders, while NOS1AP has been genetically linked to
schizophrenia, post-traumatic stress disorder, sudden cardiac death and long QT
All welcome to attend,